Clinical Trials Directory

Trials / Completed

CompletedNCT06472778

A Real-world Study in Participants With Smoldering Multiple Myeloma

Smoldering Pathway Assessment Real-World Knowledge (SPARK) Study-Retrospective Observational, Non-interventional Chart Review Study in Smoldering Multiple Myeloma

Status
Completed
Phase
Study type
Observational
Enrollment
431 (actual)
Sponsor
Janssen-Cilag Ltd. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the real-world characteristics and outcomes of participants with smoldering multiple myeloma (SMM) overall and by high-risk and non-high-risk SMM according to (AQUILA study criteria \[NCT03301220\], Mayo 20-2-20 and international myeloma working group (IMWG) 2020 risk classification models), and to evaluate the risk of progressing of SMM to multiple myeloma (MM) and outcomes in participants after progressing to MM.

Conditions

Timeline

Start date
2024-05-31
Primary completion
2025-12-31
Completion
2025-12-31
First posted
2024-06-25
Last updated
2026-04-13

Locations

29 sites across 5 countries: France, Germany, Italy, Spain, United Kingdom

Source: ClinicalTrials.gov record NCT06472778. Inclusion in this directory is not an endorsement.